Bangkok GLP-1 supply digest · May 2026 · issue 1
Weekly read on what's actually in stock at the Bangkok premium hospitals and mid-tier clinics, with price changes since last digest, regulatory movements that affect supply, and the picking question for this week. New format, weekly cadence, BKK-anchored. Issue 1.
This is issue 1 of a new weekly format · what's actually in stock at the Bangkok GLP-1 layer, what changed price-wise since last week, regulatory movements that affect supply, and the picking question for the week. Aimed at the BKK-resident expat cohort and the cross-region cohort flying in for resupply. Refreshed every Friday.
What's in stock this week (May 2 to May 9, 2026)
| Vendor | Mounjaro | Wegovy | Ozempic | Saxenda |
|---|
The pattern this week: tirzepatide fully stable across all routable Bangkok venues. Wegovy 1.7mg backordered at multiple clinics · users mid-titration on the 1.7mg dose may need to substitute Ozempic 1.0mg or push to Wegovy 2.4mg with a clinician's call.
Price changes since April 25 digest (4 weeks ago, pre-launch baseline)
Prices in USD at mid-tier clinics, May 2026 vs the pre-launch April baseline:
- Mounjaro 5mg: USD 220-380 (no change)
- Mounjaro 10mg: USD 280-460 (no change)
- Mounjaro 15mg: USD 340-520 (no change)
- Wegovy 2.4mg: USD 320-560 (no change)
- Ozempic 1.0mg: USD 180-280 (no change)
- Saxenda monthly (3 boxes): USD 510-585 (no change)
Pricing has been remarkably stable through April. Zuellig Pharma's Mounjaro distribution has held the price range through the first 11 months of Thai-FDA-approved supply; Wegovy has held its band since the 2023 launch. We are watching for any movement around the late-May VAT review and the routine June supply refresh from the regional distributors.
Regulatory movements that affect supply
Thai FDA: no new movements affecting GLP-1 supply this week. The April 2026 reaffirmation of Mounjaro's chronic weight management indication remains the most-recent material event.
BPOM (Indonesia): still tightened. Spillover effect on Bali → Bangkok cross-border patient flow remains noticeable; BIMC and Body Tonic confirmed multiple Indonesian-resident patients re-routing through Bangkok this month rather than waiting for BPOM clearance.
Vietnam MoH: semaglutide approval still pending. No timeline movement this week. Vietnam-resident expats sourcing tirzepatide via Bangkok hop remains the dominant pattern.
FDA (US): Eli Lilly Texas-court tirzepatide-compounding case has its next hearing scheduled for May 14. Outcome could shift US compounded supply but does not affect Bangkok directly. Covered in /blog/after-fda-crackdown-us-compounded-may-2026.
The picking question this week
For BKK-resident expats new to GLP-1 starting this week:
- If your route is Mounjaro: any of the 7 vendors above. Pick by location convenience and price tier. Premium-hospital tier (Bumrungrad / Samitivej / BNH / BDMS Wellness) for clinical infrastructure, mid-tier (Healthi Life / Boston Health Longevity / Fresh Genetiq) for cost-conscious + the Stripe-pay convenience.
- If your route is Wegovy at 1.7mg specifically: Bumrungrad is your most-likely-stocked option. Samitivej and Healthi Life are showing intermittent. If you can flex to 2.4mg or substitute Ozempic 1.0mg for a stabilization period, the picture loosens.
- If your route is Mounjaro at 7.5mg or 12.5mg: BNH is currently intermittent on these mid-step doses. Bumrungrad / Samitivej / BDMS Wellness are stable. If you are mid-titration BNH-anchored, call ahead to confirm before your scheduled refill.
For cross-region expats flying in this week:
- From Bali, Singapore, Hanoi, HCMC, KL, Manila: the Bangkok-hop math from each origin is in the playbook. All target compounds (Mounjaro / Wegovy / Ozempic) are stable enough this week to plan the trip with confidence. The 1.7mg Wegovy gap is the only stocking caveat.
- From the US: branded prescription routes are preferable to compounded for the May 2026 regulatory environment. The hop is real but the cost-arbitrage from US is less sharp than from SE Asia origins given US flight cost.
What we're watching for next week
- Wegovy 1.7mg restock timing across the affected clinics
- Whether the May 14 US Lilly-vs-Empower hearing shifts the US-cohort routing question
- Routine June pricing refresh from Zuellig (Mounjaro) and Novo Nordisk (Wegovy/Ozempic) Thailand distributors
- Any Thai FDA movement on Zepbound (tirzepatide weight-management indication) registration
The next digest lands May 9. If this format is useful, we keep it. If it duplicates what's already in the /supply tracker without adding value, we kill it. Subscribe to the waitlist to get the digest in your inbox if you do not want to check back manually.
The full Bangkok premium-hospital comparison is at /blog/bangkok-premium-hospitals-glp1-2026. The Bangkok-hop playbook for cross-region expats is at /blog/bangkok-glp1-hop-expat-playbook-2026. Per-vendor scorecards live at /vendor.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.
After the FDA crackdown: the state of US compounded GLP-1 in May 2026
Five months after the FDA closed enforcement discretion on 503A and 503B compounded tirzepatide and semaglutide, the US compounded-GLP-1 landscape has consolidated, contracted, and fragmented. The April 30 scorecard recap captured the snapshot. This is what changed in the four weeks after.
Bali GLP-1 supply tactical update May 2026: what's actually in stock at each clinic this month
BPOM intermittency means the existing Bali buyers guide gets stale fast. This is the May 2026 supply-state tactical · per-clinic Mounjaro and Ozempic stocking, the most-current expat-routable picks, and the Bangkok-hop fallback when the nomad-clinic layer has gaps.
The Bangkok GLP-1 hop: a practical playbook for expats in Bali, Singapore, Hanoi, HCMC, KL, Manila
Bangkok is the regional anchor for legitimately-supplied tirzepatide and semaglutide in Southeast Asia. Flight matrices, clinic-relationship cadence, cold-chain transit, customs personal-use rules per origin country, and the four-versus-twelve-week supply math.